{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:33:19Z","timestamp":1790609599009,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00213-020-05472-5","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T06:04:05Z","timestamp":1580364245000},"page":"1459-1470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"5472_CR1","unstructured":"2002 S9 (2002) Center for drug evaluation and research. Application number 21\u2013436. Medical review(s). https:\/\/www.fdagov"},{"key":"5472_CR2","doi-asserted-by":"crossref","unstructured":"Belgamwar RB, El-Sayeh HG (2011) Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev: CD006622","DOI":"10.1002\/14651858.CD006622.pub2"},{"key":"5472_CR3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"S Brooks","year":"1998","unstructured":"Brooks S, Gelman A (1998) General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7:434\u2013455","journal-title":"J Comput Graph Stat"},{"key":"5472_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","volume":"189","author":"M Cantillon","year":"2017","unstructured":"Cantillon M, Prakash A, Alexander A, Ings R, Sweitzer D, Bhat L (2017) Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophr Res 189:126\u2013133","journal-title":"Schizophr Res"},{"key":"5472_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/YIC.0000000000000123","volume":"31","author":"L Citrome","year":"2016","unstructured":"Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA (2016) The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol 31:192\u2013201","journal-title":"Int Clin Psychopharmacol"},{"key":"5472_CR6","unstructured":"Cochrane (2011) Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"5472_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","volume":"172","author":"CU Correll","year":"2015","unstructured":"Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 172:870\u2013880","journal-title":"Am J Psychiatry"},{"key":"5472_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","volume":"174","author":"CU Correll","year":"2016","unstructured":"Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Kane JM (2016) Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 174:82\u201392","journal-title":"Schizophr Res"},{"key":"5472_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1017\/S1092852900014784","volume":"11","author":"AJ Cutler","year":"2006","unstructured":"Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD (2006) The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 11:691\u2013702 quiz 719","journal-title":"CNS Spectr"},{"key":"5472_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"5472_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29:932\u2013944","journal-title":"Stat Med"},{"key":"5472_CR12","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","volume":"76","author":"S Durgam","year":"2015","unstructured":"Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Nemeth G, Meltzer HY (2015) Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry 76:e1574\u2013e1582 FDA https:\/\/www.fda.gov\/","journal-title":"J Clin Psychiatry"},{"key":"5472_CR13","first-page":"76","volume-title":"ECDEU assessment manual for psychopharmacology: US Department of Health, Education and Welfare Publication (ADM)","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology: US Department of Health, Education and Welfare Publication (ADM). National Institute of Mental Health, Rockville, pp 76\u2013338"},{"key":"5472_CR14","unstructured":"Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: Collaboration TC (ed). http:\/\/handbook.cochrane.org"},{"key":"5472_CR15","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Backers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939\u2013951","journal-title":"Lancet"},{"key":"5472_CR16","doi-asserted-by":"crossref","unstructured":"Ishigooka J, Iwashita S, Tadori Y (2018) Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci","DOI":"10.1111\/pcn.12682"},{"key":"5472_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763\u2013771","journal-title":"J Clin Psychiatry"},{"key":"5472_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4088\/JCP.v68n0206","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM, Meltzer HY, Carson WH Jr, RD MQ, Marcus RN, Sanchez R, Aripiprazole Study Group (2007) Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 68:213\u2013223","journal-title":"J Clin Psychiatry"},{"key":"5472_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","volume":"164","author":"JM Kane","year":"2015","unstructured":"Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 164:127\u2013135","journal-title":"Schizophr Res"},{"key":"5472_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261\u2013276","journal-title":"Schizophr Bull"},{"key":"5472_CR21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.2147\/NDT.S176676","volume":"14","author":"T Kishi","year":"2018","unstructured":"Kishi T, Oya K, Matsui Y, Nomura I, Sakuma K, Okuya M, Matsuda Y, Fujita K, Funahashi T, Yoshimura R, Iwata N (2018) Comparison of the efficacy and safety of 4 and 2 mg\/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. Neuropsychiatr Dis Treat 14:2519\u20132530","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5472_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1017\/S0033291718001393","volume":"49","author":"T Kishi","year":"2019","unstructured":"Kishi T, Ikuta T, Matsui Y, Inada K, Matsuda Y, Mishima K, Iwata N (2019) Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis. Psychol Med 49:772\u2013779","journal-title":"Psychol Med"},{"key":"5472_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry 18:208\u2013224","journal-title":"World Psychiatry"},{"key":"5472_CR24","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063\u20132071","journal-title":"Lancet"},{"key":"5472_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962","journal-title":"Lancet"},{"key":"5472_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bacher S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174:927\u2013942","journal-title":"Am J Psychiatry"},{"key":"5472_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","volume":"201","author":"S Leucht","year":"2018","unstructured":"Leucht S, Chaimani A, Leucht C, Huhn M, Mavridis D, Helfer B, Samara M, Cipriani A, Geddes JR, Salanti G, Davis JM (2018) 60years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response. Schizophr Res 201:315\u2013323","journal-title":"Schizophr Res"},{"key":"5472_CR28","unstructured":"Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM (2019) Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry: appiajp201919010034"},{"key":"5472_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mork A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbol TB, Kikuchi T (2014) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589\u2013604","journal-title":"J Pharmacol Exp Ther"},{"key":"5472_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","volume":"41","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN (2007) A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 41:895\u2013905","journal-title":"J Psychiatr Res"},{"key":"5472_CR31","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj 339:b2535","journal-title":"Bmj"},{"key":"5472_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","volume":"209","author":"RM Murray","year":"2016","unstructured":"Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D (2016) Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 209:361\u2013365","journal-title":"Br J Psychiatry"},{"key":"5472_CR33","unstructured":"NCT00905307 (n.d.) Study to evaluate the efficacy, safety, and tolerability of oral OPC-34712 and aripiprazole for treatment of acute schizophrenia (STEP 203). Clinical Trialsgov"},{"key":"5472_CR34","unstructured":"NCT01810380 (n.d.) Brexpiprazole in patients with acute schizophrenia. Clinical Trialsgov"},{"key":"5472_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7:64\u201377 PMDA https:\/\/www.pmda.go.jp\/english\/index.html","journal-title":"Lancet Psychiatry"},{"key":"5472_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681\u2013690","journal-title":"Arch Gen Psychiatry"},{"key":"5472_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades AE, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17:279\u2013301","journal-title":"Stat Methods Med Res"},{"key":"5472_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4088\/JCP.08r04392","volume":"70","author":"V Simon","year":"2009","unstructured":"Simon V, van Winkel R, De Hert M (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70:1041\u20131050","journal-title":"J Clin Psychiatry"},{"key":"5472_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3:285\u2013299","journal-title":"Res Synth Methods"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-020-05472-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:19:46Z","timestamp":1722374386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-020-05472-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5472"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05472-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that there are no potential conflicts of interest in relation to the subject of this study. We have had the following interests within the last 3\u00a0years.Dr. Kishi has received speaker\u2019s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Kyowa, Otsuka, Pfizer, Meiji, MSD, Sumitomo Pharmaceuticals (Suzhou), Yoshitomi, and Tanabe-Mitsubishi and has received a Health Labour Sciences Research Grant, Grant-in-Aid for Scientific Research (C), and a Fujita Health University School of Medicine research grant.Dr. Ikuta received speaker\u2019s honoraria from Eli Lilly, Daiichi Sankyo, and Dainippon Sumitomo and is a consultant for Dainippon Sumitomo.Dr. Matsuda has received speaker\u2019s honoraria from Dainippon Sumitomo, Eisai, Otsuka, Tanabe-Mitsubishi, and Pfizer and has received a grant-in-aid for Young Scientists (B).Dr. Sakuma has received speaker\u2019s honoraria from Eisai, Kissei, Meiji, Otsuka, and Torii and has received a grant-in-aid for Young Scientists (B).Dr. Iwata has received speaker\u2019s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has received research grants from Daiichi Sankyo, Dainippon Sumitomo, Meiji, and Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}